Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.

Part of paid clinical trials in Pittsburgh, Pennsylvania.

Sponsor
Pravat Mandal
Study ID
NCT07064005
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Parkinsons Disease (PD)

Eligibility Criteria

Sex
ALL
Age
50 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Gamma- glutamylcysteine — DRUG
    400 mg (two times) per day

Study Details

This study is designed l to evaluate the effects of GGC oral supplementation in early Parkinson's disease (PD) patients. The main objectives of the study are to evaluate: 1. To study the enrichment of master antioxidant, glutathione (GSH) levels in brain and blood of these PD patients compared to baseline due to GGC supplementation. 2. To study the changes in motor function, cognitive skills in PD patients due to GGC oral supplementation 3. To study impact of GGC on gut health on the PD patients.

Key Dates

Start date
Mar 23, 2026
Status verified
May 2026
Primary completion
Sep 30, 2027
Completion
Nov 27, 2027

Study Design

Enrollment
12 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION

Arms

  • Experimental: Gamma - Glutamylcysteine
    Patients will receive GGC tablet 400mg orally twice a day (morning and in the afternoon).

Primary Outcome Measure

Changes in brain glutathione levels (mM) in people with Parkinson's Disease using Magnetic Resonance Spectroscopy compared to post-supplementation with GGC. [ Time Frame: 12 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UPMC Presbyterian HospitalPittsburghPennsylvania15213
Pravat K Mandal, PhD
[email protected]
4126999561

Find similar trials in Pittsburgh, PA

By research site
UPMC Presbyterian Hospital· Pittsburgh, PA

Related Studies